CRA International, Inc.

CRA International, Inc. (CRAI) Market Cap

CRA International, Inc. has a market capitalization of $1.16B.

Price: $179.03

-4.92 (-2.67%)

Market Cap: 1.16B

NASDAQ · time unavailable

CEO: Paul A. Maleh

Sector: Industrials

Industry: Consulting Services

IPO Date: 1998-04-24

Website: https://www.crai.com

CRA International, Inc. (CRAI) - Company Information

Market Cap: 1.16B|Sector: Industrials

Company Profile

CRA International, Inc., along with its affiliated entities, delivers specialized advisory services across the domains of economics, finance, and management in the United States, the United Kingdom, and globally. The firm provides expert guidance to clients on economic and financial considerations arising from legal disputes and regulatory challenges. Additionally, it collaborates with corporations to address matters of business strategy and operational effectiveness. Its comprehensive consulting offerings encompass in-depth research and analysis, expert witness testimony, and robust support for corporate clients and legal practitioners navigating litigation and regulatory proceedings. These services cover critical areas such as finance, accounting, economics, insurance, and forensic accounting and investigations. Moreover, CRA International's management consulting capabilities are extensive, covering areas like strategy formulation, performance enhancement, corporate strategic planning, portfolio analysis, market demand forecasting, new product pricing strategies, valuation of intellectual property and other assets, competitive intelligence, and the evaluation of new supply chain opportunities. The company's clientele spans numerous industries, including communications and media; consumer, health, and wellness products; energy; entertainment and leisure; financial services; healthcare; life sciences; manufacturing; natural resources; retail and distribution; technology; and transportation. Established in 1965, CRA International, Inc. is headquartered in Boston, Massachusetts.

Analyst Sentiment

75%
Strong Buy

From 2 Active Polls

1Y Forecast: $194.00

▲ +8.4% Potential Upside

Consensus Target Metrics

Low Bound

$194

Median

$194

High Bound

$194

Average

$194

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$194.00
▲ +8.36% Upside
Low Target
$194.00
8% Risk
Median Target
$194.00
8% Mid
High Target
$194.00
8% Max
Consensus
Buy
1 / 1 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q1 2026Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MApr 4, 2026Jan 3, 2026Sep 27, 2025Jun 28, 2025Mar 29, 2025Dec 28, 2024Sep 28, 2024Jun 29, 2024
Market Cap ($M)1,1571,0751,3131,3451,2521,1751,2641,1351,177
Enterprise Value ($M)1,4051,3231,4221,5171,4561,3341,3401,2781,341
Price to Earnings Ratio (P/E)24.5924.1424.9429.3125.8316.3621.1424.9845.32
Price/Earnings-to-Growth Ratio (PEG)11.854.199.355.334.08
Price to Sales Ratio (P/S)1.505.356.677.246.706.467.166.776.87
Price to Book Ratio (P/B)5.885.426.156.676.365.175.965.556.14
Price to Free Cash Flow Ratio (P/FCF)-68.01-9.2322.2637.47268.49-14.5118.3639.69-2312.28
Enterprise Value to Sales (EV/Sales)6.587.228.167.797.347.607.627.82
Enterprise Value to EBITDA (EV/EBITDA)14.2156.3260.0459.8355.2941.2645.2652.7675.30
Debt to Equity Ratio2.501.410.600.961.140.810.490.820.98

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CRA INTERNATIONAL INC (CRAI) — Investment Overview

🧩 Business Model Overview

CRA International is a specialized professional services firm providing economic, financial, and strategy consulting for high-stakes decisions. Work typically flows from complex client needs—such as dispute resolution, regulatory proceedings, and valuation—into deliverables that rely on rigorous economic modeling, industry expertise, and expert credibility.

The value chain is characterized by (1) acquiring mandates through trusted relationships and established expert networks, (2) staffing engagements with senior consultants and domain specialists, (3) producing analysis and testimony that are designed to withstand scrutiny from adversarial parties and regulators, and (4) converting outcomes into repeat business via demonstrated competence, methodology, and familiarity with the client’s business and stakeholders.

Client stickiness is reinforced because engagements are often knowledge-intensive, fact-specific, and time-consuming to re-create—making subsequent matters more likely to be assigned to the same providers.

💰 Revenue Streams & Monetisation Model

Revenue is predominantly engagement-driven and can be broadly categorized into:

  • Litigation support and dispute consulting: damages analysis, expert testimony support, and settlement-related economic work.
  • Regulatory and policy consulting: economic analysis supporting competition/antitrust, market design, and compliance-related positions.
  • Commercial and valuation services: valuation, strategic assessment, and financial-economic modeling for transactions and strategic planning.
  • Investigations and forensic-oriented advisory: where economic/statistical methods are central to the conclusions.

Monetisation is driven by billable consultant time, senior-expert involvement, and premium pricing for work that has high evidentiary value. While most revenue is project-based (not subscription), there is a recurring element in repeat mandates and ongoing relationships with legal, compliance, and corporate strategy functions.

Primary margin drivers include: (1) utilization and labor productivity of specialized teams, (2) the ability to scale senior-expert oversight without proportionate increases in cost, and (3) engagement mix—work tied to expert credibility and complex modeling tends to support higher effective rates and pricing power.

🧠 Competitive Advantages & Market Positioning

CRA’s moat is best characterized as Intangible Assets + Switching Costs.

  • Intangible assets (credibility and expert track record): In disputes and regulatory matters, clients and decision-makers rely on analytical rigor and the credibility of the experts presenting the work. Building that reputation typically takes years of demonstrated outcomes and methodological discipline.
  • Switching costs (fact pattern and methodology depth): Each engagement involves highly specific economic assumptions, industry knowledge, and client datasets. Reconstituting models and rebuilding institutional knowledge is costly in time and risk, which discourages frequent vendor changes.
  • Barriers to entry in practice: The economics/financial expertise required to serve as expert-adjacent decision support is hard to replicate quickly, since it depends on senior talent development and proven performance under adversarial scrutiny.

Competitive benchmarking:

  • Cornerstone Research — broader footprint in economic litigation support and valuation; competes for disputes, expert testimony, and economic damages work.
  • NERA Economic Consulting (part of FTI Consulting) — strong in antitrust, disputes, and regulatory economics; competes heavily where formal economic analysis is central.
  • Brattle Group and other specialist boutique firms — compete for complex economic advisory, particularly in litigation, energy-adjacent market design, and regulatory disputes.

CRA’s positioning emphasizes depth in economic and financial advisory for complex, high-scrutiny proceedings, competing on technical credibility and team specialization rather than on scale alone.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by structural increases in the demand for economic analysis and expert decision support:

  • Rising complexity of regulation and enforcement: Antitrust, competition policy, privacy/commercial regulation, and sector-specific oversight increasingly require sophisticated economic modeling.
  • More disputes with measurable damages: Litigation and arbitration involving technology, consumer harm, commercial contracting, and infrastructure spending continues to require expert economic quantification.
  • Globalization of investigations and cross-border disputes: Multijurisdictional matters expand the addressable pool of mandates and increase the value of firms with established methodologies and experienced international teams.
  • Ongoing outsourcing of specialized expertise: Corporations and law firms often prefer external subject-matter experts for peak workload and for credibility in proceedings.

TAM expansion is driven less by simple headcount growth and more by the growing “economic-content” of disputes and regulatory actions—work that directly benefits specialist firms with established credibility.

⚠ Risk Factors to Monitor

  • Demand cyclicality and legal spend sensitivity: Mandates are tied to litigation, regulatory activity, and corporate decision-making budgets, which can soften in macro downturns.
  • Talent retention and senior-expert dependency: Specialist economics/financial advisory requires experienced teams; losing key experts can affect delivery quality and client confidence.
  • Reputational and execution risk: Engagement performance is evaluated under adversarial conditions; material errors or weak methodologies can impair future win rates.
  • Technology disruption (including AI-enabled analysis): While automation can improve internal productivity, it can also compress certain low-differentiation work. The sustainable advantage depends on whether human-led judgment, credibility, and defensibility outpace cost substitution.
  • Client concentration: A meaningful shift in spending by a small set of large clients (law firms or corporate repeat customers) can influence revenue mix and utilization.

📊 Valuation & Market View

Markets generally value specialized professional services using earnings-based multiples (EV/EBITDA or P/E), with premiums often linked to perceived margin stability, utilization discipline, and the durability of client relationships. For CRA-style businesses, valuation is typically most sensitive to:

  • Operating leverage: the ability to convert billing growth into incremental margin through utilization and staffing mix.
  • Quality of revenue: whether revenue is supported by repeat relationships and higher-value expert work rather than purely transactional assignments.
  • Credibility and backlog/visibility: investors typically focus on the stability of demand and the firm’s ability to win and retain mandates.

A key analytical lens is whether margins and earnings reflect durable, relationship-driven economics rather than short-lived swings in case volumes or pricing.

🔍 Investment Takeaway

CRA International’s long-term investment case rests on a hard-to-imitate combination of credibility (intangible assets) and switching costs created by fact-specific, knowledge-intensive engagements. In environments where economic analysis is a central input to disputes and regulatory decisions, the firm’s specialist capabilities and client stickiness can support durable earnings power, subject to execution quality and talent retention.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for CRAI.

defenseworld.net2026-07-26

Charles River Associates (NASDAQ:CRAI) Shares Gap Down – Here’s Why

Charles River Associates (NASDAQ: CRAI - Get Free Report)'s stock price gapped down prior to trading on Friday. The stock had previously closed at $167.32, but opened at $150.13. Charles River Associates shares last traded at $168.6880, with a volume of 19,303 shares. Analyst Ratings Changes Separately, Weiss Ratings downgraded Charles River Associates from a

businesswire.com2026-07-23

Charles River Associates (CRA) to Host Second-Quarter Fiscal 2026 Financial Results Conference Call on August 6

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that the company will webcast its second-quarter 2026 financial results conference call on Thursday, August 6, 2026 at 10:00 a.m. ET. The conference call will be hosted by President and Chief Executive Officer Paul Maleh, Chief Financial Officer Eric Nierenberg, and Chief Corporate Development Officer Chad Holmes. To listen to.

businesswire.com2026-07-21

Charles River Associates (CRA) Adds Kevin Williams, Yale School of Management Professor, as Academic Affiliate to Antitrust Practice

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced the addition of Kevin Williams as an Academic Affiliate in the firm's Antitrust & Competition Economics Practice. “I am pleased to welcome Kevin to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “Kevin is a recognized expert in the economics of industrial organization, with a focu.

zacks.com2026-07-16

Implied Volatility Surging for CRA International Stock Options

Investors need to pay close attention to CRAI stock based on the movements in the options market lately.

zacks.com2026-07-10

CRAI Benefits From Global Talent Pool & Shareholder-Friendly Policies

Charles River Associates' global talent network, cross-border expertise, and rising dividends and buybacks support long-term growth and enhance investor appeal.

globenewswire.com2026-07-07

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

PHILADELPHIA and VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that it has engaged Charles River Associates (CRA) (Nasdaq: CRAI) and Kaleio, Inc. to support commercial strategy, market access evaluation and brand planning for Bria-IMT.

zacks.com2026-06-10

Reasons Why You Should Hold Charles River Stock in Your Portfolio

CRAI benefits from rising demand for specialized advisory services, but AI, talent costs and fierce competition pose risks.

seekingalpha.com2026-06-05

Dividend Champion, Contender, And Challenger Highlights: Week Of June 7

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

zacks.com2026-06-03

3 Consulting Services Stocks to Consider Amid Industry Woes

Rising talent costs, persistent inflation and cautious corporate spending are weighing on the consulting services industry. Expert consultation and data-driven advisory demand are likely to aid.

gurufocus.com2026-06-03

Charles River Associates (CRA) to Present at the Sidoti Small-Cap Virtual Conference

[url="]Charles River Associates[/url] (NASDAQ: CRAI), a worldwide leader in providing [url="]economic, financial, and management consulting services[/url], tod

businesswire.com2026-06-03

Charles River Associates (CRA) to Present at the Sidoti Small-Cap Virtual Conference

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that the Company will participate in the Sidoti Small-Cap Virtual Conference on June 17 and 18, 2026. CRA Chairman and Chief Executive Officer Paul Maleh is scheduled to present at 10:00 a.m. EDT on Wednesday, June 17. A live webcast will be available on the Company's investor relations website. An archived replay will be avai.

gurufocus.com2026-05-29

CRA International Inc (CRAI) Shares Fall 6.5% -- What GF Score of 82 Tells Investors

On May 29, 2026, CRA International Inc (CRAI) shares fell 6.5% today, bringing the current price to $138.75. The stock has experienced a 52-week range of $132.1

zacks.com2026-05-13

CRAI Stock Barely Moves Since Q1 Earnings Miss & Revenue Beat

Charles River shares remained flat after Q1 results, as an earnings miss and weak 2026 revenue outlook offset revenue growth.

seekingalpha.com2026-05-09

CRA International, Inc. (CRAI) Q1 2026 Earnings Call Transcript

CRA International, Inc. (CRAI) Q1 2026 Earnings Call Transcript

zacks.com2026-05-07

CRA International (CRAI) Q1 Earnings Miss Estimates

CRA International (CRAI) came out with quarterly earnings of $1.99 per share, missing the Zacks Consensus Estimate of $2.02 per share. This compares to earnings of $2.22 per share a year ago.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-04-04

"CRAI (Q1’26 ended 2026-04-04) reported Revenue of $201.0M and Net Income of $11.1M, with EPS of $1.71 (diluted $1.69). QoQ, revenue rose ~1.0% (from $197.0M in Q4’25) while net income declined ~15.6% (from $13.2M). YoY, revenue grew ~10.5% versus $181.9M in Q1’25, and net income fell ~38.2% (from $18.0M), indicating profitability pressure despite top-line growth. Margin performance softened over the last four quarters: net margin deteriorated to 5.5% in Q1’26 from 6.7% in Q4’25 and 9.9% in Q1’25. Operating income also decreased QoQ (~12.6%). Cash flow quality weakened materially this quarter—operating cash flow was -$113.9M and free cash flow was -$116.5M, contrasting with positive FCF in prior quarters (e.g., +$58.9M in Q4’25). Balance sheet resilience looks mixed: total assets increased to $662.4M while equity declined to $198.4M; total debt rose to $70.9M and net debt improved to $38.4M. Shareholder returns appear subdued: 1-year price change is -3.8% (no momentum tailwind). Dividend yield is ~0.35%, with no clear evidence of buyback support in this quarter beyond a $21.5M repurchase."

Revenue Growth

Positive

Revenue +1.0% QoQ (196.96M to 200.98M) and +10.5% YoY (181.85M to 200.98M). Growth is positive, though not accelerating.

Profitability

Neutral

Net income -15.6% QoQ and -38.2% YoY. Net margin compressed to 5.5% in Q1’26 from 6.7% in Q4’25 and 9.9% in Q1’25, indicating margin contraction.

Cash Flow Quality

Neutral

Operating cash flow was -$113.9M and free cash flow -$116.5M in Q1’26, a sharp reversal versus Q4’25 (+$60.0M OCF; +$58.9M FCF).

Leverage & Balance Sheet

Neutral

Total assets rose to $662.4M, but equity fell to $198.4M from $213.6M. Debt declined versus Q4’25 (net debt improved to ~$38.4M), supporting balance-sheet resilience.

Shareholder Returns

Caution

Dividend yield is low (~0.35%). 1-year price performance is -3.8%, so total shareholder return is not being supported by price momentum. Q1 included buybacks (-$21.5M).

Analyst Sentiment & Valuation

Fair

Consensus price target is 194 versus current price 158.84, implying upside (~22%). However, recent fundamentals show declining profitability and negative cash flow.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

CRAI delivered a strong Q1 2026 with revenue up 10.5% to $201M, the highest quarter on record, driven by broad-based practice growth and improved consultant utilization to 77%. Non-GAAP EBITDA was $23.2M (11.5% margin), with management attributing any margin pressure primarily to higher forgivable loan amortization (6.9% of revenue; +53% YoY). They argued that when EBITDA is considered alongside forgivable amortization, the combined profitability margin is within ~20 bps of prior record levels. The quarter also showed operating strength: DSO improved to 100 days, and pipeline metrics (lead flow and project originations) hit quarterly records. Management reaffirmed full-year fiscal 2026 guidance and highlighted upper-70s utilization as the medium/long-term target. Capital deployment remained balanced—$25.3M returned via dividends and repurchases, while $62.3M funded talent investments and the revolver capacity increased to $300M for flexibility. Q&A reinforced confidence in demand durability, clarified guidance build mechanics, and discussed utilization pacing beginning January.

AI IconGrowth Catalysts

  • 8 practices growing YoY; Energy, Finance, Forensic Services and Life Sciences delivered double-digit growth; Antitrust & Competition Economics set a new quarterly revenue record
  • Antitrust & Competition Economics jointly retained for a merger between two major North American distributors (unconditional FTC clearance supported by locality-by-locality empirical analyses)
  • Forensic Services demand across ransomware, wire transfer fraud, employee misconduct, trade secret disputes; retained on privacy/advertising technology and multi-terabyte privacy class action defense
  • Energy practice momentum tied to data center growth and procurement/backstop needs; hired by PJM for high-profile backstop procurement option
  • Life Sciences practice multiple-quarter double-digit growth; European Life Sciences grew >20% YoY alongside >20% growth in European Antitrust & Competition Economics

Business Development

  • Joint retention by a merger between two of the largest North American distributors of janitorial, sanitation and food services products (FTC unconditional clearance)
  • Advised REEL International (industrial lifting/handling systems) defending a damages claim by competitor Fives ECL in the Hamburg Local Division of the Unified Patent Court; claim dismissed in February 2026
  • Supported expert testimony in Delaware Court of Chancery for the Caremark trial (food safety crisis; fiduciary duties/information systems)
  • Supported a CRA expert for Serta Simmons Bedding 2020 liability management uptier transaction (excluded vs participating lenders)
  • Advising engagements: utility client on data center tariffs and large-load risk mitigation; private equity group on commercial/regulatory due diligence for a community solar portfolio; Life Sciences board-level review strategy for immunology pharmaceutical company; global pricing study for combination therapy with Most Favored Nation policy considerations
  • Retained by a global advertising technology company for privacy class action defense (online tracking technologies)

AI IconFinancial Highlights

  • Revenue +10.5% YoY to $201 million; highest quarterly revenue in company history, surpassing Q4 fiscal 2025 record
  • Non-GAAP EBITDA $23.2 million or 11.5% of revenue (noted first quarter seasonality from annual bonus-related benefits and taxes)
  • Forgivable loan noncash amortization embedded in Q1 EBITDA: $13.8 million or 6.9% of revenue; up 53% YoY (+$4.8 million), consistent with fiscal 2026 annual profit guidance expectations
  • Reported EBITDA margin pressured by forgivable loan amortization; management stated EBITDA + forgivable amortization margin is within 20 bps YoY of record levels
  • Non-GAAP SG&A (excluding 1.5% commission to nonemployee experts): 15.6% of revenue vs 15.9% a year ago
  • Effective tax rate (non-GAAP): 30.3% vs 27.2% prior year; increase primarily due to nondeductible executive compensation and decreased share-based compensation benefit
  • DSO improved to 100 days from 108 days at Q4 fiscal 2025 (58 days billed, 42 days unbilled)

AI IconCapital Funding

  • Returned $25.3 million to shareholders in Q1: $3.8 million dividends and $21.5 million share repurchases (~116,000 shares)
  • Share repurchase program remaining availability: $44.5 million
  • Net cash outlays for talent investments: $62.3 million
  • Traditional capital expenditures: $2.6 million
  • Ending cash: $32.5 million; revolver borrowings: $192 million; net debt: $159.5 million
  • Total liquidity: $86.7 million ($32.5 million cash plus $54.2 million available credit capacity)
  • Revolver capacity increased by $50 million (from $250 million to $300 million) during the week; supports working capital and growth

AI IconStrategy & Ops

  • Optimized service portfolio via consulting team reconfiguration affecting 22 individuals across ~six practices and various corporate departments; restructuring charge $2.6 million ($1.6 million cash, $1.0 million noncash)
  • Anticipated annual cost savings from restructuring: ~ $5 million with minimal revenue impact; intends to redeploy savings into business to strengthen and pursue profitable growth
  • Talent pipeline replenishing: average weekly project lead flow and new project originations hit quarterly records; consultant headcount +2.5% YoY and utilization improved

AI IconMarket Outlook

  • Full-year fiscal 2026 guidance reaffirmed; management cited strong start, supportive market trends, and continued replenishing of sales pipeline
  • Utilization outlook: medium/long-term target to remain in upper 70s ballpark
  • Management indicated Q2 and rest of 2026 demand expected to remain strong (fingers crossed comment) but noted macro/geopolitical uncertainty in guidance context

AI IconRisks & Headwinds

  • Competitive pressure: firms continue to take share of prominent cases
  • Complexity and data burden increasing across all business units may heighten execution risk, though CRA positions as capable of handling it
  • Higher effective tax rate (non-GAAP 30.3% vs 27.2%) driven by nondeductible executive compensation and reduced share-based compensation benefit
  • Seasonality/working-capital volatility: first quarter disproportionately affected by higher employee-related benefit costs and taxes due to annual bonus payments; revolver borrowings elevated to fund annual bonuses

Q&A: Analyst Interest

  • Topic: What is driving the demand environment beyond case-filing and judgment trends? Management emphasized the last 5–6 months are higher than prior tenure patterns, pointed to cross-practice momentum (nearly all revenue from 8 practices growing >10% YoY), and attributed durability to escalating complexity and sustained lead flow rather than a single macro item. Management also noted competition keeps getting share of prominent matters.
  • Topic: How does the reported EBITDA margin movement reconcile to underlying profitability given forgivable loan amortization? Management explained the margin drop is primarily due to higher forgivable loan amortization (about 5% of revenue in 2025 to 6.9% in Q1 2026). They stated EBITDA plus forgivable amortization margin is within ~20 bps YoY versus record levels, supported by cost controls and strong utilization.
  • Topic: Guidance assumptions and utilization pacing—does hiring imply inorganic revenue and what is the utilization trajectory within the quarter? Management said revenue guidance does not assume inorganic additions because ramp timing is uncertain; profitability guidance does assume cost burden/amortization from hiring. For utilization, they reported being in the upper 70% range starting in January, not a gradual quarter-long climb, and expects upper-70s ballpark going forward with strong profitability converting to cash flow.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the CRAI Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for CRAI.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (CRAI)

© 2026 Stock Market Info — CRA International, Inc. (CRAI) Financial Profile